Background Rivaroxaban was reported as effective as traditional therapies for the acute
treatment of venous thromboembolism (VTE) with fewer major bleeding complications in the …

Background: The effectiveness and safety of acute venous thromboembolism (VTE)
treatment with rivaroxaban, demonstrated in phase-III trials, needs to be evaluated in …

Abstract Background The direct factor Xa inhibitor rivaroxaban is approved for the treatment
of venous thromboembolism (VTE), based on the results of large phase III trials. Objectives …

The effectiveness and safety of acute venous thromboembolism (VTE) treatment with
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …

Background The efficacy and safety of rivaroxaban have been demonstrated in phase 3
trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Clinical practice data on effectiveness and safety of new drugs are useful for supporting the
results from randomised clinical trials. The latter are limited in size and certain patient …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

Data on long-term effectiveness and safety of venous thromboembolism (VTE) treatment
with rivaroxaban are scarce and not available from randomized clinical trials. To supplement …

Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …